Lorena Di Carlo – General Manager, Lundbeck China
Lorena Di Carlo, a Lundbeck veteran, shares her first impressions of her six months as general manager of Lundbeck China, the strategic significance of China to Lundbeck’s global organization, the…
Address: 22F, N.138 Pudong Avenue
Shanghai 200120 P.R. China ,China
Tel: +86 21 5888 2200
Web: http://www.boehringer-ingelheim.com.cn/
Entering the Chinese market in 1994, Boehringer Ingelheim investment ushered in vigorous development. Boehringer Ingelheim has excellent products in the prescription drugs, consumer self-care medicines and animal health field in the Chinese market and are widely recognized by consumers.
Since 2002, the company has been based in Shanghai. The Zhangjiang Hi-Tech Park factory was built to demonstrate the Boehringer Ingelheim’s determination to further establish itself in China. The Zhangjiang plant has introduced the world’s most advanced pharmaceutical equipment, design and management standards to the country and is comparable to Boehringer Ingelheim plants in any part of the world. The factory operates in strict accordance to international GMP standards. Boehringer Ingelheim’s investment in China amounts $ 29,000,000. The Company has offices in Shanghai, in Beijing, Guangzhou, Shenyang, Chengdu, Nanjing, Hangzhou and has also set up branches in other places, employing a total of more than 2,000 people.
Boehringer Ingelheim’s main business in China includes prescription drugs, consumer self-care medicines and animal health. The business scope encompasses all of the country’s major cities and regions. The company will continue to pursue new drug and disease treatment programs and Boehringer Ingelheim products have gained an excellent reputation in the market, benefitting millions of patients.
Looking ahead, Boehringer Ingelheim Shanghai looks forward to even greater success in the Chinese market, including in the field of human medicine, the company wants to be the key leader in the respiratory, cardiovascular, central nervous system, diabetes and cancer fields. as well as animal health.
With a solid foundation built up over more than a century, Boehringer Ingelheim strives to make greater contributions to Chinese medical and health undertakings.
respiratory, cardiovascular, central nervous system, diabetes, oncology
Lorena Di Carlo, a Lundbeck veteran, shares her first impressions of her six months as general manager of Lundbeck China, the strategic significance of China to Lundbeck’s global organization, the…
China’s unbridled growth has spurred a vast number of overseas Chinese to return home to seek new opportunities in their transformed homeland. Affectionately known as ‘sea turtles’ because the Chinese…
Dr John Yu, co-founder and CEO of CGeneTech, shares the exciting story behind the company’s establishment in 2010; its balanced philosophy on new drug development and the progress of their…
Fendy Yanhui Feng, vice president of Eisai Co., Ltd. and president of Eisai China Holdings Ltd. and Eisai China Inc., shares the significant improvements she has made to Eisai’s China…
Research has established that proper nutrition during hospitalization helps to reduce the number of infections, the duration of treatment needed for recovery, and reduce the readmission rateCecily Gu discusses her…
Samantha Du, Chairman and CEO of Zai Lab, the flagship China biotech company, shares her inspirational story of being one of the pioneers to forge a path for Chinese biopharma…
Lydia Guo, Grace Zhao and Mendy Zhang of executive search firm Egon Zehnder outline some of the latest trends affecting the Chinese pharma sector and what they look for in…
Jay Dong, founding GM (China and APAC) and Global VP of Cell Signaling Technology, shares the company’s success in the past ten years; the economic transformation in China driving the…
Kevin Rufang Huang is the president and founder of the Chinese Organization for Rare Disorders (CORD). A rare disease patient himself, he is responsible for bringing“International Rare Disease Day” to…
What do executive recruitment firms look for when hiring country managers for multinational pharma companies in some of the world’s most challenging markets? Eric Bouteiller and Simon Wan of Cornerstone…
Dr Lingshi Tan, chairman and CEO of dMed, shares his strategic insights into the new era of Chinese biotech innovation and how it motivated him to leave Pfizer to establish…
Dr John Gong, CEO of 3D Medicines, shares the company’s ‘3D – diagnostics, data, and drug development’ approach to cancer precision medicine; his philosophy of putting patient needs at the…
See our Cookie Privacy Policy Here